Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban

Clinical Neurology and Neurosurgery

Volumn 122, Issue , 2014, Pages 131-132

  Van Hooff, Robbert Jan ^a,b   Nieboer, Koenraad ^a   De Smedt, Ann ^a,b   Yperzeele, Laetitia ^a,b   Jochmans, Kristin ^a   De Keyser, Jacques ^a,b,c   Brouns, Raf ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute stroke; Stroke therapy; Thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOGEN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

AGED; APHASIA; ATAXIC APHASIA; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EYE DISEASE; FIBRINOGEN BLOOD LEVEL; HEAD MOVEMENT; HEART ATRIUM FIBRILLATION; HEMATURIA; HEMIANOPIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LUNG EMBOLISM; MALE; MIDDLE CEREBRAL ARTERY; PARTIAL THROMBOPLASTIN TIME; SENSORY DYSFUNCTION; THROMBOCYTE COUNT; FIBRINOLYTIC THERAPY; POLYPHARMACY; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; BRAIN ISCHEMIA; FACTOR XA INHIBITORS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MORPHOLINES; POLYPHARMACY; STROKE; THIOPHENES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84902239906     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.12.029     Document Type: Letter

References (5)

1. H.P. Adams Jr., G. del Zoppo, M.J. Alberts, D.L. Bhatt, L. Brass, and A. Furlan et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke 38 2007 1655 1711 (Pubitemid 46691097)
2. C.L. Cove, and E.M. Hylek An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes J Am Heart Assoc 2 2013 e000136
3. C.E. Dempfle, and M.G. Hennerici Fibrinolyitc treatment of acute ischemic stroke for patients on new oral anticoagulant drugs Cerebrovasc Dis 32 6 2011 616 619
4. T. Steiner, M. Böhm, M. Dichgans, H.C. Diener, C. Ell, and M. Endres et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban Clin Res Cardiol 102 6 2013 Jun 399 412
5. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, L. Le Flem, and C. Guinet et al. Laboratory assessment of rivaroxaban: a review Thromb J 11 2013 11